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REVIEW
Abstract: Post-traumatic stress disorder (PTSD) is a severe anxiety disorder that may develop
after experiencing or witnessing a traumatic event. Recent clinical evidence has suggested the
involvement of neurodegenerative pathology in the illness, particularly with brain imaging
studies revealing a marked reduction in hippocampal volume. Of greater significance is that
these anatomical changes appear to be positively correlated with the degree of cognitive deficit
noted in these patients. Stress-induced increases in plasma cortisol have been implicated in
this apparent atrophy. Although not definitive, clinical studies have observed a marked
suppression of plasma cortisol in PTSD. The basis for hippocampal neurodegeneration and
cognitive decline therefore remains unclear. Stress and glucocorticoids increase glutamate
release, which is recognized as an important mediator of glucocorticoid-induced neurotoxicity.
Recent preclinical studies have also noted that glutamate and nitric oxide (NO) play a causal
role in anxiety-related behaviors. Because of the prominent role of NO in neuronal toxicity,
cellular memory processes, and as a neuromodulator, nitrergic pathways may have an important
role in stress-related hippocampal degenerative pathology and cognitive deficits seen in patients
with PTSD. This paper reviews the preclinical evidence for involvement of the NO-pathway
in PTSD, and emphasizes studies that have addressed these issues using time-dependent
sensitization – a putative animal model of PTSD.
Keywords: PTSD, nitric oxide, glutamate, GABA, glucocorticoids, NOS, stress, time-
dependent sensitization (TDS)
Introduction
Classified as an anxiety disorder, post-traumatic stress disorder (PTSD) is
characterized by hyperarousal, avoidance, and various amnesic symptoms caused by
exposure to a severe traumatic event (APA 1994) (Table 1). By definition PTSD
occurs in the aftermath of exposure to trauma, but there is growing awareness of the
importance of multiple exposures to trauma in predicting the onset and severity of
this disorder (Brewin 2001; Maes et al 2001). Nevertheless, the more severe the
initial trauma and the more intense the acute stress symptoms, the higher is the risk
for developing PTSD (Gore and Richards 2002).
The most characteristic features of PTSD are pneumonic in nature (APA 1994)
and include amnesia, flashbacks, fragmentation of memories (Elzinga and Bremner
2002), and an abnormal startle response; the latter reflecting an inability to properly
integrate memories (van der Kolk 1994). In lieu of the evidence for degeneration of
the hippocampus in patients with PTSD, a dysfunctional hippocampus may represent
the anatomic basis for the fragmentation of memory. Although glucocorticoids have
received the greatest attention with regards to the possible mechanisms involved in
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hippocampal shrinkage (McEwen 1999; Sapolsky 2000b),
their role, as well as other molecules involved in cellular
resilience, requires more stringent evaluation.
Recent preclinical studies have found that stress exerts
significant effects on nitric oxide synthase (NOS) activity,
while clinical trials have emphasized the role of gamma-
amino butyric acid (GABA)-glutamate balance as a putative
neurobiological target in the treatment of PTSD. This paper
reviews the role of GABA and glutamate in stress, especially
the preclinical evidence for involvement of the nitric oxide
(NO)-pathway in PTSD, and studies that have addressed
these issues using time-dependent sensitization – a putative
animal model of PTSD. From this point of view, we address
their role as protagonists of neuronal degeneration and
atrophy evident in neuroimaging studies of patients with
PTSD, and how this may unfold into new avenues of
treatment.
Anatomy and neurobiology of
PTSD
Brain areas accepted as critical in mediating the stress
response are the hippocampus and prefrontal cortex. These
areas are in turn affected by the stress response. Imaging
studies in PTSD patients have demonstrated volume
reductions in the hippocampus (Bremner 1999; Elzinga and
Bremner 2002), while structural changes, as well as
functional deficits have also been observed in the medial
prefrontal cortex in PTSD (Bremner 2002; Elzinga and
Bremner 2002). Proper functioning of the hippocampus is
necessary for explicit or declarative memory. Damage to
the hippocampus resulting from stress not only causes
problems in dealing with memories relating to past stressful
experiences, but also impairs new learning (Bremner 1999;
Elzinga and Bremner 2002). The prefrontal cortex, on the
other hand, plays an important role in the process of fear
conditioning, specifically with regard to extinction of
conditioned fear responses (Le Doux 1998; Hamann 2001).
In this regard, the medial prefrontal cortical areas modulate
fear responding through inhibitory connections with the
amygdala (Le Doux 1998), which in turn plays a crucial
role in fear conditioning (Akirav et al 2001).
Recent studies suggest that structural abnormalities in
PTSD may reflect either pre-trauma vulnerability or a
consequence of trauma exposure (Gilbertson et al 2002).
Furthermore, while increased plasma cortisol levels occur
immediately after or during stress (Yehuda et al 1990),
clinical studies of cortisol in PTSD have met with mixed
results. Thus, investigators have documented plasma cortisol
as unchanged (Baker et al 1999), elevated (Liberzon et al
1999b), and suppressed (Yehuda et al 2000). Given these
diverse results, the causal role for glucocorticoids in
hippocampal neurodegeneration and cognitive decline in
patients with PTSD remains unclear.
A key issue in the pathogenesis of PTSD seems to be
within associative learning and other behavioral processes
mediated by the hippocampus. These processes involve the
glutamate N-methyl-D-aspartate (NMDA) receptors
(Heresco-Levy and Javitt 1998) and the NO signaling
pathway (O’Dell et al 1994; McLeod et al 2001). Moreover,
the synaptic localization of NOS and the soluble guanylyl
cyclase (McLeod et al 2001) facilitates the functioning of
NO as a retrograde messenger – and thereby serves as a
possible modulator of long-term potentiation (LTP) (Burette
et al 2002).
LTP represents a form of synaptic learning that is known
to exist in the hippocampus, striatum, and neocortex, and
has been proposed as a cellular model for some forms of
learning and memory. LTP describes a prolonged increase
in the size of the postsynaptic response to a presynaptic
stimulus of given strength. Activation of NMDA receptors
are obligatory for the induction of the type of LTP that occurs
in the hippocampus CA1 region. These events are initiated
by Ca2+ flow through open, unblocked NMDA channels that
lead to alterations in the strength of interneuronal synaptic
connectivity (Bliss and Collingridge 1993; Bloom 2001).
In the hippocampus, LTP is most evident in the dentate gyrus
Table 1 Main symptoms of PTSD
1. Reexperiencing
• Invasive memories of the trauma
• Frequent nightmares
• Flashbacks
• Psychological and physiological reactivity to internal/external cues
resembling the trauma
2. Avoidance
• Avoiding thoughts, conversations, feelings, places, activities, and
people related to the event
• Inability to recall an important aspect of the trauma
• Loss of interest in external world and detachment from others
• Difficulty feeling and expressing positive emotion
• Lack of desire to deal with the future
3. Hyperarousal
• Anxiety and hypervigilance
• Problems with sleeping
• Difficulty in concentrating and studying
• Irritability with angry outbursts
• Constant feeling of alertness and exaggerated startle response 
Data adapted from APA (1994).
Abbreviations: PTSD, post-traumatic stress disorder.Neuropsychiatric Disease and Treatment 2005:1(2) 111
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granule cells where glutamate activation of both AMPA
(α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) and
NMDA receptors (Vallance and Collier 1994) are required.
It is interesting that prolonged loss of consciousness
following terrifying events appears to protect against the
development of PTSD (Adler 1993). Although coma is not
yet fully understood, it may involve disruption of
glutamatergic pathways (O’Brien and Nutt 1998). Similarly,
central nervous system (CNS) suppressants such as ethanol
and benzodiazepines exert some of their effect by
suppressing glutamatergic function, these frequently being
abused by patients with PTSD, possibly assisting in
preventing the reemergence of previously established
memories (Collingridge and Bliss 1995). The activation of
neuronal NO synthase (nNOS) and other Ca2+-dependant
enzymes may account for many of the beneficial as well as
deleterious affects associated with NMDA receptor
activation, including neuronal development (Garthwaite
1991), learning, and memory (Iga et al 1993), but also
cell death and neurodegeneration (Dawson VL and
Dawson TM 1995).
Role of sensitization and kindling
in PTSD
Models such as fear conditioning and kindling have been
central to our understanding of fear circuitry, particularly
through the processing of fear-relevant information between
the amygdala, locus coeruleus, hippocampus, and thalamus.
The association between stressful life events and the onset
and chronicity of psychiatric illness dates back to Kraepelin
(1921) who proposed that in depression, the illness may
become increasingly autonomous and less reliant on
environmental adversity. This mechanism may hold for most
psychiatric illnesses that are characterized by a progressive
worsening over time. The kindling phenomena was first
described by Goddard et al (1969) who noted that repeated
subthreshold electrical stimulation leads to full-blown
seizures. After sufficient repetition the seizures begin to
occur spontaneously. The kindling hypothesis therefore has
particular relevance for viewing how synapses react to
environmental stressors, and represents one way to integrate
a range of data describing the neurophysiology and
neurochemistry of the onset, long-term development, and
treatment responsiveness of PTSD. The primary neural
substrate of kindling involves glutamate and NMDA
receptor activation, with inhibitory GABA pathways
exerting essentially a permissive role on the kindling action
of glutamate (Post and Weiss 1998). This evidence not only
emphasizes the involvement of excitatory glutamatergic and
inhibitory GABA’ergic pathways in the neuropathology of
PTSD (Chambers et al 1999; Vaiva et al 2004), but also the
process of sensitization and kindling in the neuro-
development of the disorder.
Time-dependent sensitization
(TDS): an animal model of PTSD
Animal models of PTSD have utilized intense stressors,
aversive challenges, and situational reminders of a traumatic
stress in an attempt to model long-term effects on behavioral,
autonomic, and hormonal responses seen in humans with
PTSD (Uys et al 2003). As alluded to earlier, the concept of
sensitization is an important concept in the neuro-
development of PTSD and is emphasized by repeated trauma
over time by stress–restress in the TDS model.
In this model, animals are exposed to a single session of
prolonged stress (eg, 2 h restraint followed by a 20 min
forced swim, followed by exposure to ether or halothane
vapors). The animals are allowed to recover for a week and
are then subjected to a brief restress on day 7 (30 min of
restraint stress or 20 min swim stress), the rationale being
that the frequency of exposure to situational reminders
contributes to the maintenance over time of fear-related
behavioral disturbances. The model has proven to resemble
the clinical situation with accurate face validity (how well
the model resembles the psychiatric condition), construct
validity (how well the model is consistent with theoretical
rationale), and predictive validity (how the model responds
to the drugs used in humans with PTSD).
Face validity. Stress-restress evokes a pronounced
acoustic startle response (Kahn and Liberzon 2004), as well
as spatial memory deficits together with lowered plasma
corticosterone (Harvey, Naciti, et al 2003), consistent with
clinical findings in PTSD. The TDS model emphasizes the
role of prior trauma in predicting subsequent dysfunction,
allows for the study of bidirectional expression of symptoms
(enhanced or reduced responsiveness to environmental
stimuli), and provides credible intra-subject variation
(Yehuda and Antelman 1993). These represent important
phenomenological and biological correlates of PTSD.
Construct validity. The model has proved valuable for
studying hypothalamic-pituitary-adrenal (HPA)
abnormalities relevant to PTSD (Yehuda and Antelman
1993), in that animals subjected to TDS display the enhanced
sensitivity to negative glucocorticoid feedback that is oftenNeuropsychiatric Disease and Treatment 2005:1(2) 112
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characteristic of PTSD (Liberzon et al 1997; Liberzon,
Lopez, et al 1999; Harvey, Naciti, et al 2003). Of particular
importance is that stress–restress leads to changes in
hippocampal serotonin (5HT) 5HT1A and prefrontal cortex
5HT2A receptors (Harvey, Naciti, et al 2003), which are brain
areas that are intimately involved in memory and stress
responsiveness. These data also correlate positively with the
accepted role of 5HT in the pathology of the disease and its
responsiveness to serotonin reuptake inhibitors (SRIs)
(Argypolous et al 2000). In the context of this review, TDS
stress also evokes distinct changes in GABA and glutamate
receptors (Harvey et al 2004).
Predictive validity. The effects of TDS-induced stress on
spatial memory are attenuated by the 5HT reuptake inhibitor,
fluoxetine (Harvey et al 2005), and by the steroid synthesis
inhibitor, ketoconazole (Brand et al 2004). These data
correlate positively with the putative causal role of serotonin
and glucocorticoids in PTSD-associated memory changes.
How may glucocorticoids be
involved in the biobehavioral
pathology of PTSD?
Exposure to an acute stressful event leads to a profound
release of glucocorticoids from the adrenal cortex (Bremner
1999). Important to note is that glucocorticoids have
bidirectional effects on memory function. While
hippocampal damage is associated with exposure to
excessive levels of glucocorticoids (Bremner et al 1999),
too low levels of glucocorticoids are also detrimental for
normal hippocampal function (de Kloet et al 1999).
Repeated administration of corticosterone decreases
5-HT1A-mediated inhibition of the hippocampus (Karten et
al 1999) through a process that occurs at the level of protein
synthesis (Bijak et al 2001), resulting in reduced 5-HT1A
receptor expression (Montgomery et al 2001). Consequently,
stress-induced corticosterone release immediately after
stress will make the hippocampus more vulnerable to the
laying down of long-term emotion-driven memories.
In both PTSD and TDS stress, increased sensitivity of
hippocampal glucocorticoid receptors (Yehuda 1998) and
release of glutamate may heighten the vulnerability of the
hippocampus to atrophy, even in the absence of higher
cortisol levels (Sapolsky 2000b). Indeed, marked changes
in glutamate NMDA receptors have been observed following
TDS stress (Harvey et al 2004). Furthermore, high levels of
corticosterone induce a rapid and non-genomic prolongation
of NMDA receptor-mediated Ca
2+ elevation in cultured rat
hippocampal neurons (Takahashi et al 2002), while stress-
mediated changes in hippocampal spine densities are NMDA
receptor dependent (Shors et al 2004). These effects will
further compromise hippocampal function, resulting in
decreased spatial memory performance and reduced
hippocampal volume as noted in PTSD patients.
Dysfunctional glucocorticoid-glutamate activity,
described above, will lay the foundation for an impaired
ability of neurons to survive coincident insults, particularly
worsening neurotoxicity evoked by adverse conditions such
as seizures, hypoxia-ischemia, metabolic poisons,
hypoglycemia, oxidative stress, and exposure to excessive
glucocorticoids (Sapolsky 2000b). The profound effect of
glucocorticoids on hippocampal volume is clearly illustrated
in patients with Cushing’s disorder, with smaller
hippocampal volumes being reported in these patients
(Starkman et al 1992). Although the hippocampus normally
regulates glucocorticoid release through inhibitory effects
on the HPA axis (Bremner 1999; Bremner et al 1999),
hippocampal damage would result in disruption of this
negative feedback loop, increasing the exposure of the
hippocampus to glucocorticoid toxicity (Sapolsky 2000a,
2000b). However, abnormally low glucocorticoid levels are
also associated with reduced hippocampal function (de Kloet
et al 1999). For example, adrenalectomy results in a
significant reduction in LTP, while exposure to stress results
in a further reduction in LTP (Shors et al 1990).
The role of glucocorticoids in the neuropathology and
development of PTSD can therefore not be underestimated.
However, establishing its exact contribution is difficult
considering the varied results obtained in clinical studies
(Baker et al 1999; Liberzon, Abelson, et al 1999; Yehuda et
al 2000). Nevertheless, of particular interest is that the
paradoxical and rather unexpected observation of reduced
cortisol in PTSD is closely emulated by TDS stress in
animals (Liberzon et al 1997; Liberzon, Lopez et al 1999;
Harvey, Naciti, et al 2003). These data suggest that a
decreased cortisol level is conducive to decreased memory
performance (Harvey, Naciti, et al 2003). The association
between hypocortisolemia and neurodegeneration appears
contradictory. However, despite the implications for
glucocorticoid-induced hippocampal damage in stress and
anxiety disorders, they may not be solely responsible for
the hippocampal damage and subsequent memory deficits
observed in PTSD.
Although the massive release of glucocorticoids during
and immediately following exposure to trauma may result
in hippocampal atrophy (Starkman et al 1992; BremnerNeuropsychiatric Disease and Treatment 2005:1(2) 113
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1999; Sapolsky 2000b), PTSD is a disorder that develops
and worsens over time (Bremner 1999). It is thus possible
that massive glucocorticoid secretion due to acute trauma
exposure is only the first step in a cascade of events leading
to later neurodegeneration and hippocampal atrophy with
subsequent memory deficits. This cascade may involve
kindling and sensitization as well as a host of molecular
messengers, both neuroprotective and neurotoxic in nature,
that will ultimately determine the progressive deterioration
of neuronal function eventually culminating in the
behavioral pathology typical of PTSD. Although various
possible candidates could be discussed, for the purpose of
this review we will maintain our focus on the glutamate-
NO-pathway and the effects of TDS stress.
Glutamate-NMDA receptor
pathway
Alterations of glutamatergic and NMDA receptor functions
have been proposed to play a role in the etiology of PTSD
in humans (van der Kolk 1994; Dawson VL and Dawson TM
1995; Chambers et al 1999). The NMDA receptor is involved
in the normal processes of memory encoding while
overstimulation of the NMDA receptor leads to the
formation of strongly ingrained emotional memories via
excessive mobilization of free cytosolic Ca
2+. However, high
levels of NMDA-Ca
2+ activity are toxic to cells (McCaslin
and Oh 1995) and, much like cortisol and memory described
earlier, a delicate balance is needed for optimal neuronal
function that does not hold any threat to neuronal survival.
Both stress and glucocorticoids have been found to
increase glutamate concentrations in the hippocampal
synapse, acknowledged as a prime mediator of
glucocorticoid-induced neurotoxicity (Sapolsky 2000b). The
extreme neurotoxic potential of glutamate is well recognized
in Alzheimer’s disease (Louzada et al 2004), schizophrenia
(Heresco-Levy 1999), and possibly affective illnesses
(Harvey 1996). One of the cardinal symptoms of
Alzheimer’s disease is cognitive impairment and loss of
mnemonic function, and has its origin in excessive glutamate
activity (Dawson VL and Dawson TM 1995). PTSD,
similarly, is characterized by a loss of cognitive abilities
with evidence for increased glutamatergic activity
(Chambers et al 1999). In support of this, a recent pilot study
by Heresco-Levy and colleagues (2002) report on the clinical
evidence for efficacy of D-cycloserine, a partial agonist at
the glycine regulatory site on the NMDA receptor, in the
treatment of PTSD.
Stress and glucocorticoids not only increase glutamate
concentrations in the hippocampus, but glucocorticoids also
selectively increase glutamate accumulation in response to
excitotoxic insults in this brain region (Sapolsky 2000a).
Thus, hippocampal damage resulting from the effects of
increased levels of glucocorticoids due to trauma exposure
will further elevate levels of glutamate, thus potentiating
the neurotoxic process. It is therefore clear that, while
increased levels of glucocorticoids may initiate hippocampal
damage, it also activates other neurotoxic pathways that may
drive neuronal damage over a protracted period after the
traumatic event.
Recently, various animal studies have begun to tease out
the role of glutamate during severe stress. For example, mice
lacking a fully functional glutamate NMDA receptor are
less sensitive to stress induced by the elevated plus-maze,
light-dark box, and forced swimming tests (Miyamoto et al
2002). Using the TDS model, Kahn and Liberzon (2004)
describe the inhibitory effect of the glutamate receptor
inhibitor, topiramate, on an exaggerated acoustic startle
response induced by TDS stress. Focusing more on the long-
term sequelae of acute severe stress, we noted that TDS
stress evokes a profound effect on glutamate receptors in
the hippocampus of rats three weeks after stress exposure
(Harvey et al 2004). In the latter study, TDS stress induced
a significant down-regulation of hippocampal NMDA
receptors. Despite the indication that overstimulation of the
NMDA receptor might explain the neurodegeneration
observed in PTSD, preclinical studies have found that
inhibition of glutamate reuptake, resulting in increased
glutamate levels, leads to a decrease in NMDA receptor
density (Cebers et al 1999). This is suggested as a possible
neuroprotective mechanism to counteract NMDA receptor
overstimulation (Naskar and Dreyer 2001).
Nitric oxide and its relevance to
stress and PTSD
Nitric oxide (NO) pathway
Glutamatergic stimulation of NMDA receptors activates a
number of enzymes including NOS, cyclooxygenases,
proteases, lipases, and protein kinases by evoking a long-
lasting (100 millisecond) Ca
2+-ion influx. In the presence
of calmodulin, Ca
2+ activates NOS, which converts the
amino-acid L-arginine to Nω-hydroxy-L-arginine, which is
further converted to NO and L-citrulline (Nathan 1992;
Knowles and Moncada 1994). A small gaseous molecule
(MW 30Da) with a biological half-life of minutes, NO isNeuropsychiatric Disease and Treatment 2005:1(2) 114
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rapidly degraded to nitrites and nitrates. However, its great
lipid solubility affords it the unique ability to move quickly
within and between cells.
NOS exist in three different isoforms that are either
constitutive or inducible (Table 2). The activity of the
constitutive NOS depends on Ca
2+ and calmodulin, whereas
the inducible NOS is independent of Ca
2+. Endothelial eNOS
is mainly located in the cell membrane, neuronal nNOS in
neuronal cells, while inducible iNOS is located in
macrophages and glial cells (Nathan 1992). All NOS
isoforms are dependant on NADPH (β-nicotinamide adenine
dinucleotide phosphate) and calmodulin. In iNOS,
calmodulin is present in a tightly bound form, such that
iNOS produces NO in a sustained manner in the presence
of adequate substrate (Marletta 1993). Calcium-calmodulin
binds to the constitutive enzyme in a reversible manner, but
binds irreversibly to the inducible enzyme, so that neurons
and endothelial cells containing the constitutive enzyme
produce receptor-regulated pulses of NO, while the
inducible enzyme in macrophages and microglia produces
sustained levels of NO in response to cytokines that are not
regulated by receptors (McCaslin and Oh 1995).
Soluble guanylate cyclase represents the most important
NO receptor in the brain (Dawson VL and Dawson TM
1995), with its activation by NO following glutamate-
mediated activation of the NMDA receptor leading to an
increase in the second messenger – cyclic guanosine
monophosphate (cGMP) (Fedele et al 2001). Important
neuronal effects of cGMP include activation of G-kinase,
activation or inhibition of phosphodiesterase and subsequent
effects on cyclic adenosine monophosphate (cAMP), effects
on ion channels and G-proteins, and neurotransmitter release
(Harvey 1996; Prast and Philippu 2001). All these actions
exert a significant effect on neuronal function. The effects
of cGMP are terminated by the phosphodiesterase (PDE)
family, among which PDE 3 and PDE 5 are considered
specific for cGMP (Soderling and Beavo 2000).
NO news or good news
NO may possess both neuroprotective and neurodestructive
properties (Dawson VL and Dawson TM 1995; McCaslin
and Oh 1995). By virtue of its unpaired electron, NO may
promote the formation of free radicals and has been linked
to various neurodegenerative processes (Ischiropoulos and
Beckham 2003). However, it has also been reported to exert
a protective action in neurodegenerative disorders (Robb
and Connor 2002). Concerning the former, nitrosylation,
DNA damage, lipid peroxidation, and energy depletion may
contribute to NO-mediated neurotoxicity (Cuzzocrea et al
2001), while its antioxidant properties (Wink et al 1999)
and ability to suppress expression of iNOS (Colasanti and
Suzuki 2000) may contribute a neuroprotective effect.
Moreover, by inhibiting its own synthesis (Griscavage et al
1995) and by down-regulating the NMDA receptor by
S-nitrosylation at the redox-sensitive site on the receptor
(Tanaka et al 1993; McCaslin and Oh 1995), NO will
negatively influence its own synthesis and activation. The
importance of NO-cGMP in the pathology and treatment of
neuropsychiatric illness is clear in the literature, eg,
depression (Harvey, McEwen, et al 2003), schizophrenia
Table 2 NOS isoforms
Neural Inducible Endothelial
(nNOS, type 1) (iNOS, type 2 ) (eNOS, type 3 )
Cells first identified in Neurons Macrophages Endothelium
Other cells expressing Myocytes Astrocytes Neurons
Astrocytes Microglia
Intracellular localization Soluble or membrane bound Soluble or membrane bound Largely membrane bound
Ca
2+ dependency Activity depends on Activity is independent of Activity depends on
elevated Ca2+ elevated Ca2+ elevated Ca2+
Expression Constitutive inducible under Inducible Constitutive
certain circumstances, eg, trauma
Amounts of NO released Small, pulses Large, continuous Small, pulses
Proposed function Regulation Host defense Regulation
Activators Glutamate Lipopolysaccharide Acetylcholine
Noradrenaline
Data adapted from Yun et al (1997) and Moncada et al (1997).Neuropsychiatric Disease and Treatment 2005:1(2) 115
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(Baba et al 2004), bipolar disorder (Yanik et al 2004), and
AIDS dementia (Vincent et al 1999).
Stress and NO
Several findings indicate that NO plays an important role in
anxiety-related disorders. High concentrations of NOS are
found in brain regions involved in the modulation of anxiety
and defensive behavior (Vincent and Kimura 1992), and
exposure to stressful stimuli has been found to induce the
activation of NO-producing neurons in the amygdala,
hypothalamus, peri-aquaductal grey, and pedunculopontine
tegmental nucleus (Krukoff and Khalili 1997). It is therefore
not surprising that behavioral and pharmacological studies
have associated dysfunctional NMDA-NO-cGMP activity
with anxiety states. Consequently, NMDA receptor
antagonists (Padovan et al 2000), guanylate cyclase
inhibitors (Eroglu and Caglayan 1997; Heiberg et al 2002),
and NOS inhibitors (Volke, Wegener, Bourin, et al 2003)
all demonstrate significant anxiolytic properties in animal
models of anxiety. Moreover, inhibition of cGMP
breakdown by coadministration of the cGMP-selective
PDE inhibitor, sildenafil, causes anxiogenic effects in the
mouse elevated plus maze (Volke, Wegener, Vasar 2003;
Kurt et al 2004).
Interestingly, antidepressants that have proved useful in
treating PTSD also inhibit NOS in the hippocampus
(Wegener et al 2003) as well as modulate NMDA receptors
(Skolnik 1999), thus further confirming the potential role
of this pathway in the pathology and pharmacology of
anxiety and stress-related disorders. It is in this context
noteworthy that several in vitro studies have shown that
activation of postsynaptic 5-HT2A/2C receptors decrease
cGMP levels generated in response to NMDA administration
(Marcoli et al 1997; Maura et al 2000). The inhibitory action
of the 5HT2A receptor on cGMP may afford a means
whereby 5HT and SRIs may treat PTSD.
Stress increases glutamate (Magarinos and McEwen
1995) and 5HT release (Joseph and Kennett 1983;
Vahabzadeh and Fillenz 1994) in the hippocampus, with
the subsequent activation of 5HT2A receptors (Vaidya et al
1999). The result is the genesis of an anxiety state as well
as down-regulation of brain-derived neurotrophic factor
(BDNF) expression (Vaidya et al 1999). The latter event
will adversely affect neuronal function and integrity, such
that the biobehavioral and neurodegenerative changes that
occur in PTSD are mediated by glutamate but driven by
excessive 5HT. In support of this, the 5HT reuptake
enhancer, tianeptine, reverses stress-induced decreases in
hippocampal neurogenesis (Czeh et al 2001), while central
depletion of 5HT prevents TDS stress-induced hippocampal
5HT1A receptor changes (Harvey et al 2005).
Studies in animals using the TDS model describe an
immediate elevation in NOS activity that is sustained for a
period of 3 weeks post-TDS stress (Table 3). This protracted
elevation in NO-production in the hippocampus is driven
primarily by the iNOS isoform (Harvey et al 2004).
Similarly, increased expression of nNOS (De Oliviera et al
2000) and iNOS (Madrigal et al 2001, 2003) has been noted
to occur in limbic brain regions following acute restraint
stress in rats.
Of particular significance is that TDS stress-induced
iNOS activation is inhibited by the glucocorticoid synthesis
inhibitor, ketoconazole (Harvey et al 2004). Moreover,
ketoconazole has been shown to inhibit development of
anxious behavior in rats exposed to stressors (Cohen et al
2000). In this manner, NO contributes to the neuro-
degenerative process initiated by an acute increase in
glucocorticoids. Thus, while an initial activation of
constitutive NOS may follow acute stress (De Oliveira et al
2000), iNOS appears to play a more prominent role during
chronic stress (Homayoun et al 2002). Since PTSD
represents a form of chronic, repeated stress due to
flashbacks and re-experiencing, this is of major significance
considering that iNOS-activity is increased over a sustained
period post stress. iNOS in neighboring astrocytes and glia
produce NO in a sustained manner, thus producing increased
levels of NO, resulting in the formation of long-lived oxidant
species such as peroxynitrite, and culminating in local
neuronal damage and hippocampal shrinkage, as observed
in patients with PTSD.
Inhibition of TDS-induced activation of iNOS with
ketoconazole also brings a strong association with stress-
induced release of cortisol. iNOS is activated by cytokines
(Dawson VL and Dawson TM 1995) – pivotal modulators
of inflammatory processes (Campbell et al 2003). Psycho-
Table 3 Kinetic data for hippocampal NOS in control animals,
in animals immediately after the acute stressors (day 1; acute),
after the re-stress (day 7), and on day 21 post stress (ps).
Vmax Km
Group (mean ± sem) (mean ± sem) N
Control 6.18 ± 3.15 3.77 ± 2.46 15
Acute 12.04 ± 1.43a 3.54 ± 2.10 8
Re-stress 12.35 ± 6.85
a 3.17 ± 1.80 6
Day 21 ps 16.86 ± 6.76
a 3.16 ± 1.16 20
Data adapted from Harvey et al (2004) and Oosthuizen F (2003 unpub).
a p < 0.05 compared with control (Dunnetts test).Neuropsychiatric Disease and Treatment 2005:1(2) 116
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logical stress in humans is associated with increased
secretion of proinflammatory cytokines such as
interleukin-6 (Maes et al 1999). High levels of cerebrospinal
fluid interleukin-6 have been measured in patients with PTSD
(Baker et al 2001). Interleukin-6 secretion is suppressed by
glucocorticoids (Baker et al 2001) such that under conditions
when glucocorticoid levels are low in PTSD, this may allow
an unopposed increase in interleukin-6 secretion, with
subsequent increase in iNOS activation.
Since NO is able to down-regulate its own synthesis both
directly on NOS (Griscavage et al 1995) and via down-
regulation of the NMDA receptor (McCaslin and Oh 1995),
these neuroprotective mechanisms may comprise a possible
protective role for NO in the initial stages post stress.
Neuronal NOS may, however, be more sensitive than iNOS
to the above inhibiting action of NO (Griscavage et al 1995).
This suggests that overproduction of NO in the hippocampus
following TDS stress more likely is the result of iNOS
induction and not activation of nNOS. Indeed, activation of
NOS by TDS stress is selectively blocked by the selective
iNOS inhibitor, aminoguanidine and not the selective nNOS
inhibitor, 7-nitroindazole (Harvey et al 2004). The decrease
in NMDA receptor density following TDS stress (Harvey
et al 2004) further underlines the involvement of iNOS and
Figure 1 Role of nNOS in TDS stress. Immediately after an acute stress, NO is released via the action of adrenal glucocorticoids and the sequential release of
glutamate in the hippocampus, activation of NMDA receptors, and the influx of Ca2+ leading to the activation of nNOS. 5HT released as a consequence of stress acts
on 5HT2 receptors activating constitutive nNOS via the protein kinase C (PKC) pathway. NO then exerts various neuromodulatory effects (Prast and Phillippu 2001)
as well as promotes the cellular processes of plasticity and memory either via itself, or by the synthesis of its second messenger, cGMP. However, NO prevents this
cascade from progressing indefinitely by inhibiting its own synthesis (nNOS), inhibiting NMDA receptor function, promoting GABA release that further attenuates
glutamate activity and by inhibiting the expression of iNOS. 5HT also inhibits guanylate cyclase-cGMP, thereby also effectively down-regulating the NO-pathway.
Raised glucocorticoids inhibit cytokine release preventing any possible mobilization of iNOS. Shortly after the immediate response to a stressful event, glucorticoids
then shut down the cortisol response by feedback inhibition of the HPA axis. Solid lines indicate activation; broken lines indicate inhibition. (Abbreviations are listed
at the end of the paper.)
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that may be involved here, and how it maintains or loses its
efficacy in regulating the normal response to trauma, is an
important consideration.
NO via nNOS is increased after acute stress (Krukoff
and Khalilli 1997; De Oliviera et al 2000) where NO acts
predominantly as a neuromodulator by decreasing glutamate
release, NO release, NOS activity, and increasing GABA
release (see Figure 1 for detailed description) (Harvey 1996;
Prast and Philippu 2001). Under these conditions, it will
have a beneficial effect on memory consolidation (McLeod
et al 2001). Thus, this acute increase in NO may underlie a
normal physiological and protective role for NO in the early
stages of stress. However, under conditions of protracted
reexposure to stressful stimuli, as is the case after TDS stress,
a different dynamic may be involved that predicts a gradual
loss of homeostatic regulatory mechanisms controlling the
process of consolidating or extinguishing trauma-related
not nNOS, since iNOS activation is not regulated by
neuronal receptors (McCaslin and Oh 1995).
Acute versus chronic stress and
dysregulation of GABA-glutamate
balance
The natural development of PTSD is dependent on various
comorbid factors, including the nature of the prior trauma
and intra-subject variation. Of course a question relating to
the natural development of PTSD post stress is why various
people exposed to the same stressor respond differently,
some developing PTSD and others not (McNally 1998). This
suggests that a natural protective mechanism is in place to
prevent excessive release of neurodestructive forces after a
severely stressful event and which may not be adequate in
patients that eventually develop the disorder. The mechanism
Figure 2 Role of iNOS in TDS stress. Under conditions of prolonged, recurrent stress, glucocorticoids fail to shut down the stress response leading to overt release
of catecholamines and indolamines. In addition, a reactive hyperresponsiveness of the HPA axis ensues resulting in gross inhibition of glucorticoid release resulting in
hypocortisolemia and disinhibition of cytokine expression. The result is an increased synthesis of IL-6 and subsequent expression of iNOS in local glia and astrocytes.
The latter begins producing cell-toxic levels of NO for a protracted period, while an up-regulated state of the glucocorticoid receptor will increase susceptibility to
cell toxic events, with profound consequences for the hippocampus. In an attempt to shut off excessive excitotoxic activity, NMDA receptors are down-regulated,
leading to deficits in critical NMDA-driven cellular events such as neuroplasticity. Moreover, excessive NO inhibits GABA release thus destabilizing critical GABA
glutamate balance. Activated iNOS in the CNS can also promote sympatho-adrenal outflow, complementing that already induced by raised CRF, thereby further
increasing plasma catecholamines, worsening the state of hyperarousal already present. Solid lines indicate activation; broken lines indicate inhibition.
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memories and culminating in iNOS activation (see Figure 2
for detailed description). On the positive side, TDS stress-
induced NOS activation has been found to result in a
decrease in NMDA receptor density (Harvey et al 2004)
that will adversely affect glutamate-driven LTP and
consequent memory formation. This reactive response may
also represent a form of neuroprotection as well as
attenuation of trauma-related memories.
Another key player involved in cellular resilience is
GABA. It is of major significance that TDS stress-induced
activation of hippocampal iNOS and the down-regulation
of NMDA receptors described above are associated with a
significant attenuation of total hippocampal GABA (Harvey
et al 2004). GABA occupies a critical role in inhibiting
glutamatergic transmission via presynaptic GABA-B
heteroreceptors (Yamada et al 1999). Further, swim stress-
induced GABA release in the hippocampus is potentiated
by NO (Engelman et al 2002), suggesting an important
protective mechanism to curb excessive glutamate-NOS
activation through actions on GABA release (Figure 1).
Acute stress increases GABA (Engelmann et al 2002),
possibly an immediate response to quench the excitotoxic
burst of glutamate. However, it would appear that under
conditions of repeated trauma, as with TDS, this protective
effect of GABA is lost. Within this same context, it is
pertinent to note that NO also inhibits NMDA receptor-
mediated GABA release (Moller et al 1995), such that raised
NO depletes neuronal GABA thus leaving the excitotoxic
effects of glutamate unopposed (Figure 2).
GABA pathways play an important role in regulating
normal affective state (Shiah and Yatham 1998), while also
forming an integral part of the stress response. If GABA
does indeed play a neuroprotective role in the central nervous
system by opposing excitotoxic insults resulting from
glutamate, what is the status of GABA in PTSD, and why
does GABA not protect against neurotoxic insults resulting
in hippocampal damage and memory deficits seen in PTSD?
GABA has been studied in PTSD to a limited degree,
although a recent paper has indicated that post-trauma
GABA plasma levels are low and may represent a predictive
factor in the development of acute post-traumatic stress
disorder (Vaiva et al 2004). In fact, people with panic
disorder also appear to present with abnormally low GABA
levels (Goddard et al 2004). The latter clinical data are
reminiscent of that obtained in animals subjected to TDS
(Harvey et al 2004). Thus, under conditions of chronic,
recurrent stress, the role of GABA under these conditions
either changes or becomes depleted and is no longer able to
function optimally as expected. Untreated, PTSD will get
progressively worse, with escalating GABA-glutamate
imbalance with profound neurodegenerative consequences.
A unifying hypothesis
Acute stress is therefore associated with the release of
glucocorticoids, as well as 5HT, glutamate, and NO in the
hippocampus. The immediate increase in glucocorticoids
acts on hippocampal glucocorticoid receptors, normally
unresponsive to low circulating levels of cortisol, while
glutamate activates hippocampal NMDA receptors (see
Figure 3 for detailed description). These combined responses
act to facilitate learning and the laying down of trauma-
related memories. Continued activation of hippocampal
glucocorticoid and NMDA receptors over a protracted
period, as may occur through flashbacks and reexperiencing,
will result in the excessive consolidation of trauma
memories. The associated release of GABA after acute
trauma, together with feedback inhibition of cortisol on the
HPA axis, represents the normal homeostatic response that
essentially counters the abnormal laying down of these
memories. In addition, acute release of NO via nNOS and
NMDA receptor activation down-regulates the NMDA
receptor, while localized release of 5HT will attenuate the
mobilization of Ca
2+, NO, and cGMP (Marcoli et al 1997;
Maura et al 2000). This will also prevent excessive emotional
memory consolidation (see Figure 1). Together, these
processes represent an immediate response to trauma and
persons that spontaneously remit. However, in patients
subjected to severe emotional trauma, and who later develop
PTSD, parts of or all of these mechanisms may be
compromised so that the acute stress response continues
indefinitely, eventually developing into a chronic, recurring
stress response.
Although studies of cortisol levels in PTSD have
produced mixed results, clinical findings suggest that low
cortisol levels in PTSD may constitute a vulnerability marker
related to chronic PTSD in addition to being a state-related
characteristic of acute/chronic PTSD (Yehuda et al 2000).
A major function of cortisol may be to contain stress-
activated reactions, with the HPA response ultimately being
terminated by the negative feedback inhibition of cortisol
at pituitary, hypothalamus, and extra-hypothalamic brain
sites (Yehuda et al 2000). However, suppressed cortisol that
has been evident in PTSD may possibly be mediated by a
gradual hypersensitization of the HPA axis in the aftermath
of the initial stressors (Yehuda et al 2000). This phenomenon
has also been described in animals subjected to TDS stressNeuropsychiatric Disease and Treatment 2005:1(2) 119
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(Liberzon et al 1997; Harvey, Naciti, et al 2003). In chronic
PTSD, low cortisol levels are noted in the presence of high
catecholamine levels (Yehuda et al 1997), and it has since
been suggested that individuals who develop PTSD respond
to a traumatic event by failing to release sufficient levels of
cortisol for a long enough period of time to shut down
sympathetic nervous system responses to stress (Yehuda and
Harvey 1997), especially increased release of noradrenaline
and 5HT (Figure 3). Afferent NA’ergic neurons from the
amygdala innervating the hippocampus will facilitate LTP
and the laying down of emotional memories (Figure 3).
Increased sensitivity of hippocampal glucocorticoid
receptors in PTSD (Yehuda 1998) together with the release
of glutamate heighten the vulnerability of the hippocampus
to atrophy even in the absence of higher cortisol levels
(Sapolsky 2000b). In addition, stress-induced release of 5HT
in the hippocampus (Linthorst et al 2002; Hajos-Korcsok et
al 2003) may further provoke glutamate release in the
absence of hypercortisolemia (McEwen 1997). At this point,
hypersensitization of the HPA axis has occurred resulting
in hypocortisolemia. The resultant disinhibition of cytokines
due to the lack of adequate cortisol release favors the release
of proinflammatory cytokines, particularly IL-6, and the
increased expression of iNOS and COX (Figure 2). With
repeated trauma, NO originally produced as a
neuroprotectant from constitutive NOS now takes on its
malignant alter ego courtesy of iNOS. Of significance is
that iNOS, and the activation of cyclooxygenase, may be
responsible for the central activation of sympathoadrenal
outflow induced by corticotrophin (CRF) (Okada et al 2003).
Since CRF is already raised in PTSD (Sautter et al 2003),
this will aggravate the peripheral manifestations of PTSD,
including hyperarousal (Figure 2). The end scenario is the
protracted release of cell- and neurotoxic levels of NO,
culminating in neuronal degeneration, hippocampal
shrinkage, and the behavioral and emotional sequelae that
characterizes PTSD.
Clinical implications
The above theoretical depiction of how NO may influence
the stress axis, and in this manner determine whether the
body reacts adversely or not to a severe stressor, is
speculative at this time. Nevertheless, a small clinical study
in acute PTSD has hinted of the possible involvement of
NO in PTSD (Yeh et al 2002), while evidence using the
Figure 3 Neuroanatomy of memory and TDS stress. Acute moderate to high stress activates serotonergic neurons in the hippocampus to release 5HT. 5HT then
activates postsynaptic 5HT1A receptors that inhibit the process of hippocampal LTP, dependent on glutamate-NO mechanisms, and effectively suppress the encoding
of excessive emotional memory. However, 5HT will also stimulate the release of corticotrophin (ACTH) from the hypothalamus, resulting in the secretion of
glucocorticoids. Activation of the glucocorticoid receptor in the hippocampus inhibits the expression of 5HT1A receptors, thereby preventing 5HT1A receptors from
inhibiting LTP-mediated hippocampal memory formation, while the subsequent release of glutamate evoked by glucocorticoids will further promote inappropriate
memory consolidation. As the stressor increases in intensity, or becomes recurrent, the amygdala is activated, which further activates hypothalamic glucocorticoid
release and reinforces hippocampal LTP via noradrenergic mechanisms, while the absence of adequate 5HT1A-mediated suppression of hippocampal LTP, together with
excessive glutamatergic activity, all combine to promote the consolidation of emotional-driven memories.
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TDS model of PTSD has revealed some distinct parallels
with this hypothesis.
Given the possible causal role of the NO-pathway in
PTSD, how may one address the question of adequate
treatment of the disorder? Viewing the preclinical evidence
presented by the TDS studies, a particularly attractive
approach would be the use of the steroid synthesis inhibitor
KCZ in the immediate post-stress period. While mefipristone
has recently been used in a clinical study in depression
(Belanoff et al 2002), this approach has not been explored
in PTSD. The idea of using this class of drug is, however,
gaining increased recognition as a possible avenue for future
research in anxiety and stress disorders (Strohle 2003).
Apart from its antiglucocorticoid properties, KCZ may
offer something unique. Like mefipristone and metyrapone,
KCZ is a well established pharmacological tool used to
inhibit adrenal steroid synthesis by binding the heme iron
of cytochrome P450 isoforms, mediating steroid
hydroxylation reactions (Wolff et al 1993). TDS studies
(Brand et al 2004; Harvey et al 2004) indicate that early
increases in glucocorticoids immediately after the initial
stressor may be critical for the protracted effects of repeated
trauma on spatial memory, 5HT receptors, and NOS activity.
An interesting observation was the ability of KCZ to
increase the dissociation constant (Km) of hippocampal
NOS. This observation strongly suggests that KCZ may also
be affecting NOS directly and independently of released
glucocorticoids by binding to a critical site on the enzyme.
Indeed, NOS bears striking homology to CYP450 (Bredt et
al 1991), while KCZ binding to the heme structure within
NOS has been found to reduce the maximal velocity of the
enzyme (Wolff et al 1993). Moreover, KCZ is a competitive
inhibitor of the obligatory NOS cofactor, calmodulin,
thereby preventing formation of NO (Wolff et al 1993).
Given the pharmacological evidence for the involvement of
iNOS in TDS stress (Harvey et al 2004), it is of particular
interest that KCZ inhibits iNOS expression (Baroni et al
1999). This strongly suggests that KCZ is able to reverse
the increase in NOS activity evoked by stress-restress and,
furthermore, also posits a possible dual mode of action for
KCZ in preventing trauma-related sequelae in PTSD by
suppressing the immediate release of glucocorticoids,
blocking hypersensitive glucocorticoid receptors and/or
preventing any subsequent NO-driven neuronal events.
Considering the important role that the SRIs have in the
treatment of PTSD, it is of interest that patients suffering
from depression have an increased level of nitrogen oxides
(NOx) compared with healthy controls (Finkel et al 1996;
Suzuki et al 2001), and that this is reduced following
treatment with paroxetine (Finkel et al 1996). Since SRIs
have been found to inhibit NOS activity in key limbic brain
areas as measured by microdialysis (Wegener et al 2003),
these findings indirectly suggest the pharmacological
relevance of NOS inhibition with paroxetine during the
treatment of depression. Similar proof-of-concept studies
have not been undertaken in PTSD. Nevertheless, the
aforementioned studies in depression not only emphasizes
the role of NOS as a putative new target in the treatment of
anxiety and stress-related disorders, but also associates
current treatment modalities for PTSD with clinically
relevant actions on the NO pathway.
In conclusion, animal studies employing TDS stress
provide evidence that NO has a definite role in the
pathophysiology of repeated trauma, particularly the
induction of iNOS and the protracted release of cell-toxic
amounts of NO. TDS-induced hypocortisolemia may set the
scene for increased IL-6 release that will promote iNOS
expression. Moreover, TDS evokes profound changes in
limbic GABA-glutamate function that, together with the
elevated NO levels, may underlie the neurodegenerative
symptoms evident in PTSD, including hippocampal
shrinkage and various memory changes, such as
reexperiencing, cognitive disturbances, and amnesia.
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